SYRE Stock Summary and Trading Ideas (Spyre Therapeutics | NASDAQ:SYRE)

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Spyre Therapeutics trades on the NASDAQ stock market under the symbol SYRE.

As of November 13, 2026, SYRE stock price climbed to $104.00 with 723,222 million shares trading.

SYRE has a beta of 1.53, meaning it tends to be more sensitive to market movements. SYRE has a correlation of 0.10 to the broad based SPY ETF.

SYRE has a market cap of $9.72 billion. This is considered a Mid Cap stock.

The top ETF exchange traded funds that SYRE belongs to (by Net Assets): VTI, IWM, XBI, VB, VBR.

SYRE has outperformed the market in the last year with a price return of +359.6% while the SPY ETF gained +13.4%. SYRE has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +2.1% and +7.7%, respectively, while the SPY returned -2.8% and -0.2%, respectively.

SYRE support price is $99.20 and resistance is $106.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SYRE shares will trade within this expected range on the day.